Skip to main content

Table 3 Univariate and multivariate analyses for progression-free and overall survival using the Cox proportional hazard model

From: Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

Variables PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (years)
 <55 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 ≥55 0.99 (0.67–1.44) 0.939 1.33 (0.80–2.20) 0.268 1.14 (0.67–1.92) 0.634 1.51 (0.75–3.04) 0.245
ASA
 1–2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 3–4 2.29 (1.37–3.84) 0.002 2.38 (1.26–4.51) 0.008 3.12 (1.64–5.90) < 0.001 3.24 (1.54–6.82) 0.009
Baseline CA-125 level (U/ml)
 ≤800 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 >800 1.04 (0.71–1.53) 0.826 1.14 (0.69–1.90) 0.605 0.79 (0.47–1.34) 0.382 0.93 (0.45–1.91) 0.838
FIGO stage
 III 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 IV 0.91 (0.62–1.33) 0.629 0.74 (0.47–1.18) 0.210 0.75 (0.44–1.26) 0.277 0.62 (0.32–1.24) 0.177
Histology
 Others 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Mucinous 2.64 (1.54–4.50) < 0.001 2.31 (1.26–4.24) 0.007 4.69 (2.48–8.85) < 0.001 3.24 (1.54–6.82) 0.002
 Clear cell 2.10 (1.30–3.42) 0.003 1.92 (1.12–3.29) 0.017 2.62 (1.37–4.99) 0.004 2.56 (1.21–5.30) 0.013
Residual disease
 ≤1 cm 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 >1 cm 2.86 (1.75–4.66) < 0.001 2.40 (1.43–4.04) 0.001 3.46 (1.89–6.33) < 0.001 2.43 (1.28–4.63) 0.007
Surgery extent
 Standard 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Radical 0.94 (0.64–1.39) 0.771 1.75 (1.02–2.99) 0.042 0.98 (0.57–1.67) 0.933 1.86 (0.97–3.56) 0.062
LND
 No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Yes 0.67 (0.17–2.76) 0.004 0.33 (0.18–0.61) < 0.001 0.36 (0.09–1.49) 0.002 0.32 (0.16–0.62) 0.001
LN metastasis
 No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Yes 1.03 (0.25–4.26) 0.074 2.89 (1.65–5.07) < 0.001 0.46 (0.11–1.97) 0.553 1.78 (0.74–4.32) 0.201
  1. PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists, CA-125 cancer antigen 125, FIGO Federation of Gynecology and Obstetrics, M/C Mucinous/Clear, LND lymph node dissection, LN lymph node
\